文献速递眼底病与葡萄膜炎青光眼

重复玻璃体腔注射贝伐珠单抗与青光眼手术风险的关联

Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery.
PubMed 文献 · JAMA Ophthalmol · 2017-01-01

该巢式病例对照研究利用加拿大不列颠哥伦比亚省大型人群健康数据库,纳入2009年1月1日至2013年12月31日因渗出性年龄相关性黄斑变性接受玻璃体腔贝伐珠单抗注射的患者,比较青光眼手术风险与每年注射次数的关系。结果显示每年注射7次及以上者青光眼手术调整率比为2.48(95%CI 1.25-4.93),每年4至6次者调整率比为1.65%(95%CI 0.84-3.23),方向相同但未达统计学显著。

要点

  • 每年玻璃体腔注射贝伐珠单抗7次及以上与青光眼手术风险升高相关,调整率比2.48(95%CI 1.25-4.93)。
  • 每年注射4至6次者的调整率比为1.65%(95%CI 0.84-3.23),方向相同但未达统计学显著。
  • 病例组每年注射7次及以上者较对照组多10.3%。

核心结论

  • 这项大型药物流行病学研究提示,每年7次及以上玻璃体腔贝伐珠单抗注射与青光眼手术风险升高相关,每年4至6次注射的率比方向相同但未达统计学显著。

研究设计与样本

  • 巢式病例对照研究,数据来自加拿大不列颠哥伦比亚省卫生部支持的大型人群链接健康数据库。
  • 研究对象为2009年1月1日至2013年12月31日因渗出性年龄相关性黄斑变性接受玻璃体腔贝伐珠单抗注射的全部眼科患者。
  • 病例通过小梁切除术、复杂小梁切除术、青光眼引流装置和睫状体破坏性手术的手术编码识别,每例匹配10例对照,匹配因素为年龄、既存青光眼、日历时间和随访时间。
  • 数据分析时间为2016年2月23日至2016年11月14日。

主要发现

  • 共识别74例青光眼手术病例和740例对照,病例组平均(标准差)年龄81.3(8.4)岁,对照组81.4(7.9)岁。
  • 病例组男性多于对照组,分别为38例(51.4%)和272例(36.8%)。
  • 每年接受7次及以上注射者青光眼手术调整率比为2.48(95%CI 1.25-4.93)。
  • 病例组每年7次及以上注射者较对照组多10.3%。
  • 每年接受4至6次注射者与3次及以下者相比,调整率比为1.65%(95%CI 0.84-3.23)。

关键数值与推荐

  • 每年玻璃体腔贝伐珠单抗注射7次及以上者青光眼手术调整率比为2.48(95%CI 1.25-4.93)。
  • 每年玻璃体腔贝伐珠单抗注射4至6次者与3次及以下者相比,调整率比为1.65%(95%CI 0.84-3.23)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intravitreous injections of anti-vascular endothelial growth factor (VEGF) agents are associated with a sustained increase in intraocular pressure. This sustained elevated intraocular pressure could lead to higher rates of glaucoma surgery to lower this pressure. OBJECTIVE: To determine the risk of glaucoma surgery following repeated intravitreous bevacizumab injections. DESIGN, SETTING, PARTICIPANTS: This nested, case-control study acquired and analyzed data from large, population-based, linked health databases supported by the British Columbia Ministry of Health in Canada. Study participants included all patients with ophthalmic issues in British Columbia, such as those of the Provincial Retinal Diseases Treatment Program, who had received intravitreous bevacizumab injections for exudative age-related macular degeneration between January 1, 2009, and December 31, 2013. Cases were identified using glaucoma surgical codes for trabeculectomy, complicated trabeculectomy, glaucoma drainage device, and cycloablative procedure. For each case, 10 controls were identified and matched for age, preexisting glaucoma, calendar time, and follow-up time. The number of intravitreous bevacizumab injections received per year-3 or fewer, 4 to 6, or 7 or more-was determined for both cases and controls. Data analysis was performed from February 23, 2016, to November 14, 2016. MAIN OUTCOMES AND MEASURES: Risk of glaucoma surgery compared with the number of intravitreous bevacizumab injections per year in cases and controls. Rate ratios were adjusted for covariates (diabetes mellitus, myocardial infarction, stroke, and verteporfin use). RESULTS: Seventy-four cases of glaucoma surgery and 740 controls were identified, with a mean (SD) age of 81.3 (8.4) years for cases and 81.4 (7.9) for controls. The case group had more males than the control group (38 [51.4%] vs 272 [36.8%]). The adjusted rate ratio of glaucoma surgery among those who received 7 or more injections per year was 2.48 (95% CI, 1.25-4.93). There was a 10.3% higher number of 7 or more injections among cases compared with controls. The adjusted rate ratio for those who received 4 to 6 injections per year compared with those who received 3 or fewer was 1.65% (95% CI, 0.84-3.23). CONCLUSIONS AND RELEVANCE: Findings from this large, pharmacoepidemiologic study suggest that 7 or more intravitreous injections of bevacizumab annually is associated with a higher risk of glaucoma surgery and that 4 to 6 injections per year show a nonstatistically significant rate ratio in the same direction.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Eadie BD, Etminan M, Carleton BC, et al. Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery. JAMA Ophthalmol. 2017. PMID: 28301639. doi:10.1001/jamaophthalmol.2017.0059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。